Systematic Review with Meta-Analysis: Efficacy and Safety of Direct-Acting Antivirals for Chronic Hepatitis C Genotypes 5 and 6

Table 5

Safety of DAA regimens on HCV genotype 5 and 6 patients.

Regimen	Study	Duration (weeks)	Total patients	AE rate (%)	SAE rate (%)	Pooled SAE rate (95% CI)
GENOTYPE 5
SOF/LDV	Abergel et al. [20]	12	41	80	2.4	NA
GENOTYPE 6
SOF + RBV	Lai et al. [28]	12	3	—	0	NA
	Lai et al. [28]	16	4	—	0	NA
	Lai et al. [28]	24	4	—	0	NA
SOF/VEL	Curry et al. [21]	24	1	—	0	NA
SOF/LDV	Nguyen et al. [30]	8	20	10	0	NA
	Nguyen et al. [30]	12	40	8	5	1.7% (0%, 8.2%)
	Gane et al. [24]	12	25	85	4
	Thuy et al. [31]	12	86	—	0
	Thuy et al. [31]	24	20	—	0	NA
SOF/LDV + RBV	Thuy et al. [31]	12	39	—	0	NA
	Thuy et al. [31]	24	30	—	0	NA
SOF/VEL/VOX	Gane et al. [25]	8	1	—	0	NA
	Gane et al. [25]	12	2	—	0	NA

SOF, sofosbuvir; VEL, velpatasvir; LDV, ledipasvir; VOX, voxilaprevir; PR, PegIFN + ribavirin; RBV, ribavirin; AE, adverse event; SAE, serious adverse event; NA, nonapplicable. Standard dose of each drug was as follows: SOF, 400 mg per day; VEL, 100 mg per day; LDV, 90 mg per day; VOX, 100 mg per day; PegIFN 180 μg per week; RBV 1000–1200 mg per day. The confidence intervals were computed with the exact method, as recommended by Nyaga et al. [19] who developed the statistical program used for pooling in this study.